China Pharma Holdings Debt to Equity Ratio 2012-2026 | CPHI
Current and historical debt to equity ratio values for China Pharma Holdings (CPHI) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. China Pharma Holdings debt/equity for the three months ending March 31, 2026 was 0.00.
| China Pharma Holdings Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-03-31 | $0.01B | $0.04B | 0.22 |
| 2025-12-31 | $0.01B | $0.02B | 0.36 |
| 2025-09-30 | $0.01B | $0.01B | 0.90 |
| 2025-06-30 | $0.01B | $0.01B | 1.13 |
| 2025-03-31 | $0.01B | $0.01B | 1.04 |
| 2024-12-31 | $0.01B | $0.01B | 0.92 |
| 2024-09-30 | $0.01B | $0.01B | 1.06 |
| 2024-06-30 | $0.01B | $0.01B | 0.93 |
| 2024-03-31 | $0.01B | $0.01B | 0.95 |
| 2023-12-31 | $0.01B | $0.01B | 1.21 |
| 2023-09-30 | $0.01B | $0.01B | 1.51 |
| 2023-06-30 | $0.01B | $0.00B | 2.61 |
| 2023-03-31 | $0.01B | $0.01B | 2.72 |
| 2022-12-31 | $0.01B | $0.00B | 3.15 |
| 2022-09-30 | $0.01B | $0.00B | 4.72 |
| 2022-06-30 | $0.01B | $0.00B | 3.45 |
| 2022-03-31 | $0.02B | $0.01B | 2.94 |
| 2021-12-31 | $0.02B | $0.01B | 2.76 |
| 2021-09-30 | $0.01B | $0.01B | 1.65 |
| 2021-06-30 | $0.01B | $0.01B | 2.06 |
| 2021-03-31 | $0.01B | $0.01B | 1.77 |
| 2020-12-31 | $0.01B | $0.01B | 1.64 |
| 2020-09-30 | $0.01B | $0.01B | 1.69 |
| 2020-06-30 | $0.02B | $0.01B | 1.76 |
| 2020-03-31 | $0.01B | $0.01B | 1.68 |
| 2019-12-31 | $0.01B | $0.01B | 1.41 |
| 2019-09-30 | $0.01B | $0.03B | 0.46 |
| 2019-06-30 | $0.01B | $0.03B | 0.49 |
| 2019-03-31 | $0.02B | $0.03B | 0.48 |
| 2018-12-31 | $0.02B | $0.03B | 0.50 |
| 2018-09-30 | $0.02B | $0.04B | 0.40 |
| 2018-06-30 | $0.02B | $0.04B | 0.42 |
| 2018-03-31 | $0.02B | $0.04B | 0.40 |
| 2017-12-31 | $0.02B | $0.04B | 0.39 |
| 2017-09-30 | $0.02B | $0.06B | 0.32 |
| 2017-06-30 | $0.02B | $0.06B | 0.35 |
| 2017-03-31 | $0.02B | $0.06B | 0.34 |
| 2016-12-31 | $0.02B | $0.06B | 0.33 |
| 2016-09-30 | $0.02B | $0.07B | 0.35 |
| 2016-06-30 | $0.03B | $0.07B | 0.37 |
| 2016-03-31 | $0.03B | $0.07B | 0.36 |
| 2015-12-31 | $0.02B | $0.07B | 0.33 |
| 2015-09-30 | $0.03B | $0.08B | 0.35 |
| 2015-06-30 | $0.03B | $0.10B | 0.28 |
| 2015-03-31 | $0.03B | $0.09B | 0.33 |
| 2014-12-31 | $0.03B | $0.09B | 0.31 |
| 2014-09-30 | $0.03B | $0.12B | 0.23 |
| 2014-06-30 | $0.03B | $0.12B | 0.21 |
| 2014-03-31 | $0.03B | $0.13B | 0.19 |
| 2013-12-31 | $0.03B | $0.13B | 0.19 |
| 2013-09-30 | $0.02B | $0.14B | 0.14 |
| 2013-06-30 | $0.02B | $0.14B | 0.10 |
| 2013-03-31 | $0.01B | $0.15B | 0.09 |
| 2012-12-31 | $0.02B | $0.15B | 0.10 |
| 2012-09-30 | $0.02B | $0.15B | 0.11 |
| 2012-06-30 | $0.02B | $0.15B | 0.11 |
| 2012-03-31 | $0.02B | $0.15B | 0.12 |
| 2011-12-31 | $0.01B | $0.14B | 0.10 |
| 2011-09-30 | $0.01B | $0.14B | 0.10 |
| 2011-06-30 | $0.01B | $0.13B | 0.10 |
| 2011-03-31 | $0.01B | $0.12B | 0.11 |
| 2010-12-31 | $0.01B | $0.12B | 0.12 |
| 2010-09-30 | $0.01B | $0.11B | 0.10 |
| 2010-06-30 | $0.01B | $0.10B | 0.12 |
| 2010-03-31 | $0.01B | $0.10B | 0.11 |
| 2009-12-31 | $0.01B | $0.09B | 0.15 |
| 2009-09-30 | $0.01B | $0.09B | 0.12 |
| 2009-06-30 | $0.01B | $0.08B | 0.10 |
| 2009-03-31 | $0.01B | $0.07B | 0.09 |
| 2008-12-31 | $0.01B | $0.07B | 0.08 |
| 2008-09-30 | $0.00B | $0.06B | 0.04 |
| 2008-06-30 | $0.01B | $0.06B | 0.08 |
| 2008-03-31 | $0.01B | $0.05B | 0.11 |
| 2007-12-31 | $0.00B | $0.04B | 0.10 |
| 2007-09-30 | $0.01B | $0.04B | 0.24 |
| 2007-06-30 | $0.01B | $0.03B | 0.26 |
| 2007-03-31 | $0.01B | $0.03B | 0.30 |
| 2006-12-31 | $0.01B | $0.02B | 0.37 |
| 2006-09-30 | $0.01B | $0.02B | 0.49 |
| 2006-06-30 | $0.01B | $0.02B | 0.42 |
| 2006-03-31 | $0.01B | $0.01B | 0.52 |
| 2005-12-31 | $0.01B | $0.01B | 0.50 |
| 2005-09-30 | $0.02B | $0.01B | 3.35 |
| 2005-06-30 | $0.00B | 0.00 | |
| 2005-03-31 | $0.00B | $0.00B | -1.00 |
| 2004-12-31 | $0.00B | $0.00B | -1.00 |
| 2004-09-30 | $0.00B | $0.00B | -1.00 |
| 2004-06-30 | $0.00B | $0.00B | -1.00 |
| 2004-03-31 | $0.00B | $0.00B | -1.09 |
| 2003-12-31 | $0.00B | $0.00B | -1.00 |
| 2003-09-30 | $0.00B | $0.00B | -1.01 |
| 2003-06-30 | $0.00B | 0.00 | |
| 2003-03-31 | $0.00B | $0.00B | -1.48 |
| 2002-12-31 | $0.00B | $0.00B | -1.58 |
| 2002-09-30 | $0.00B | $0.00B | -1.75 |
| 2002-06-30 | $0.00B | 0.00 | |
| 2002-03-31 | $0.00B | $0.00B | -6.46 |
| 2001-12-31 | $0.00B | $0.00B | -4.15 |
| 2001-09-30 | $0.00B | $0.00B | -6.97 |
| 2001-06-30 | $0.00B | $0.00B | -10.06 |
| 2001-03-31 | $0.00B | 0.00 | |
| 2000-12-31 | $0.00B | 0.00 | |
| 2000-09-30 | $0.00B | 0.00 | |
| 2000-06-30 | $0.00B | 0.00 | |
| 2000-03-31 | $0.00B | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.026B | $0.004B |
| CHINA PHARMA HOLDINGS, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd. (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |